Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid SignalsGulidanna Shayan, Robert L. Ferris, James Kyle Bryan et al.|Clinical Cancer Research|2017Cited by 80
Correlation of anti-tumor adaptive immunity with clinical response in a phase II “Window” trial of neoadjuvant cetuximab in patients with resectable stage III-IV head and neck squamous carcinoma (HNSCC).Robert L. Ferris, Julie E. Bauman, Seungwon Kim et al.|Journal of Clinical Oncology|2016Cited by 9